Biotica Technology ltd., was a biotech company which focused on optimised polyketide therapeutics for high-value indications. Following successful partnerships with leading pharmaceutical companies including Wyeth and GSK, the company was eventually dissolved on the 12th September 2015. It was estimated that about £15 million had been invested in the business.

Their technology platform was based on manipulation of the microbial genetics to make improved analogues of natural product polyketides in a similar way to Kosan Biosciences. This eventually led to a successful patent appeal at the EPO.

Biotica Technology Ltd.

Sanglifehrins

Sanglifehrin is a mixed polyketide / non-ribosomal peptide natural product found to be a potent cyclophilin inhibitor and antiviral. Biotica had been developing analogues of this for Hepatitis C in 2011, in particular BC556 and the sangamides. BC556 and the sangamides were acquired by Neurovive, a Swedish mitochondrial medicine company in 2013.

Biotica Technology Ltd.

Rapamycins

Biotica discovered and developed analogues of rapamycin, a potent polyketide mTOR inhibitor, which were eventually licensed to Wyeth in 2006 in a deal worth up to $195 million. Following acquisition of Wyeth by Pfizer, these rapalogs were reacquired by Biotica in 2011.

Biotica Technology Ltd.

Erythromycins

Biotica discovered and developed analogues of the polyketide antibiotic erythromycin for use in inflammatory diseases, which were licensed to GSK in 2009 in a deal worth up to £89 million.

Administration and sale of assets

Following entering administration in 2012, the assets of Biotica were eventually sold for a total of £500K to companies including the Swedish Pharmaceutical company Neurovive and the British biotech Isomerase Therapeutics.

References

British companies established in 1996

Technology companies of the United Kingdom

1996 establishments in the United Kingdom